author-photo

Jeffrey Matous

University of Maryland, Baltimore

126

Papers

4418

Citations

Citation Trend

Filter By

Papers (88) Sort By

Journal Conference Others

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex;IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (5)
Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

2020 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (64)
Patient-Reported Outcomes from Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

2019 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)